NANOG and neoplasm: After determining the analytical and clinical sensitivity of a panel of three genes (CD24, CD49f, and NANOG) in a set of primary tumours with the matched urine, we evaluated the clinical utility of this panel of three CSC-related molecules in an independent cohort of urine samples from 60 UCB and 183 control subjects.